Our products

Patients are at the heart of everything we do. Using our expertise and passion for science, we develop innovative solutions that directly address patients’ unmet needs.

Pain is one of the most common reasons why people seek medical help. Experts estimate that tens of millions of people experience moderate to severe pain with no access to adequate treatment. Chronic pain is a widespread health problem and although few people die of pain, many die in pain, and even more live in pain.

Pain has an enormous impact on quality of life: from low functionality to anxiety and depression, the comorbidities associated with chronic pain heavily impact the lives of patients with intractable pain and it is only understandable that patients with chronic pain hold huge hopes for effective and innovative solutions.

To harness the power of science, we carry out integrated research and development to find innovative solutions for the treatment of pain whether such solutions are drugs or state-of-the-art technologies, our objective is to relieve pain.
Understanding the patients’ journey is key to our work as it contextualizes our research and helps us understand where we need to create value along that journey from the first onset of symptoms to treatment initiation and beyond.
Actively involving patients during research and development is key as it enables Grünenthal to integrate real-life experiences into the study design and ultimately, to create solutions that really improve their lives.

We are tirelessly developing life-changing innovations that challenge the status quo.

Working hand-in-hand with patients, academics, healthcare professionals, and policymakers, we are determined to develop unique solutions addressing diseases with high unmet needs. If we can have a significant and real impact on these people’s lives, then we have made their hopes a reality.

¹ Treede RD, et al. Pain 2015 Jun;156(6):1003-1007.
² Pain Alliance Europe, 2017, Survey on Chronic Pain 2017, Diagnosis, Treatment and Impact of Pain.

Product Portfolio Grünenthal Pharma Ltd.

The product information provided on this site is intended for residents of Ireland only.

The links below will direct you to medicines.ie, an external website providing information about medicines in Ireland, including the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SPC).
The following documents are hosted externally. Grünenthal Pharma Ltd. is not responsible for the content of external sites.

We understand you may wish to report side effects or make a quality complaint. You can do this as follows:

Adverse events & Quality complaint reporting by Healthcare Professionals

Adverse events should be reported to

HPRA Pharmacovigilance, Earls fort Terrace, Dublin 2.
Telephone: +353 1 676 4971
Fax: +353 1 676 2517
Email: medsafety@hpra.ie
Reporting forms and information can be found at www.hpra.ie.

Adverse events should also be reported to Grünenthal Ltd.

Free phone: +44  800 2545540
Email: medicalinformationie@grunenthal.com

Reporting of side effects by patients/carers, members of the public

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.  You can also report side effects directly to

HPRA Pharmacovigilance, Earls fort Terrace, Dublin 2.
Telephone: +353 1 676 4971.
Fax: +353 1 676 2517.
Email: medsafety@hpra.ie
Reporting forms and information can be found at www.hpra.ie.

Quality complaints should also be reported.

If you report side effects or other issues regarding the safeness or quality of our products directly to Grünenthal Ltd, we will be legally bound to deal with your communication and may have to contact you for clarification purposes. Subsequently, we may have to notify the health authorities.

For patients and members of the public, your information will be forwarded in pseudonymised form, that means no information by which you may be directly identified will be passed on. We may also have to forward this information to our group companies and cooperation partners, to the extent these are likewise obliged to notify their respective health authorities.

Statement regarding the responsible use of opioid-based medicines
General considerations for the management of pain with any medication that contains an opioid mechanism of action.

All opioid medications are not authorized for all types of pain indication. Always refer to the product prescribing information

An individualized, patient-centered approach for the diagnosis and treatment of pain is essential to establish a therapeutic alliance between patient and clinician.(1)

To optimize opioid treatment :
- It is important to optimally use multimodal, non-opioid approaches in acute and chronic pain before escalating to opioids or in conjunction with opioid therapy (1)
- Opioids should be used only when benefits for pain and function are expected to outweigh risks (2)
- Consider patient variables that may affect opioid dose for each patient prior to opioid use (1)
- During ongoing opioid therapy, clinician should collaborate with patients to evaluate and carefully weigh benefits and risks of continuing opioid therapy and exercise care when increasing, continuing, or reducing opioid dosage (2)
- Make a careful selection of patients, abuse risk factors evaluated, and regular monitoring and follow-up implemented to ensure that opioids are used appropriately and in alignment with treatment goals (pain intensity and functionality) as agreed with the patient (4-5)
- Make patients aware of the potential side effects of opioids and the potential for developing tolerance, dependence and addiction (4-5).
- Addiction is possible even when opioids are taken as directed (6)
- Signs of opioid use disorder should be monitored and addressed (4-5)
If an opioid is authorized and selected for treatment of acute pain, please consider :
- The use should be for the shortest necessary time (1)
If an opioid is authorized and selected for treatment of chronic pain, please consider :
- To continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety (2)
- Regular monitoring, clinical reviews , re-evaluations are required for long-term opioid treatment to assess pain control, impact on lifestyle, physical and psychological well-being, side effects and continued need for treatment (3-5)
- How opioid therapy will be discontinued if benefits do not outweigh risks (CDC new ref), incl. tapering down the dose where possible (4-5)
Patients and the general public can benefit from clear educational materials and awareness interventions to support the responsible use of opioids (7)

References:
1. DHHS Pain Management Best Practices Inter-Agency Taskforce Report May 2019 pmtf-final-report-2019-05-23.pdf (hhs.gov)
2. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 Recommendations and Reports / November 4, 2022 / 71(3);1–95 CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 | MMWR
3. O’Brien T et al. Eur J Pain 2017;21:3-192
4. Faculty of Pain Medicine, Opioids Aware Opioids Aware | Faculty of Pain Medicine (fpm.ac.uk) Accessed February 2024
5. Kosten TR et al, Scie Pract. Perspect 2002;1:13-20
6. Rosenblum A et al Exp. Clin. Psychopharmacol. 2008;16(5):405-416
7. OECD Health Policy. Addressing Problematic opioid use in OECD Countries May 2019 http://www.oecd.org/health/addressing-problematic-opioid-use-in-oecd-countries-a18286f0-en.htm
M-N/A-DK-04-24-0003

M-ALL-IE-11-24-0001 - January 2024